Clinical Trial

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase one trial to determine if genetically engineered lymphocytes can be safely delivered to patients with metastatic melanoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2012-04-25; most recent amendment 2020-10-29.
Status change: Recruiting → Active, Not Recruiting 2018-05-21
Status change: Not Yet Recruiting → Recruiting 2012-07-24
Trial Details
NCT Number NCT01586403
Lead Sponsor Loyola University
Collaborators: National Cancer Institute (NCI)
Conditions Melanoma
Enrollment 14 participants
Start Date 2012-07
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2020-10-30